#### Pedro Pedro Rosa Rosa-Neto

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1972093/pedro-pedro-rosa-rosa-neto-publications-by-year.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

283 papers 8,289 citations

46 h-index

83 g-index

318 ext. papers

10,960 ext. citations

6.4 avg, IF

L-index

#	Paper	IF	Citations
283	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease <i>EBioMedicine</i> , <b>2022</b> , 76, 103836	8.8	4
282	Clozapine induces astrocyte-dependent FDG-PET hypometabolism European Journal of Nuclear Medicine and Molecular Imaging, <b>2022</b> , 1	8.8	2
281	Comparing tau status determined via plasma pTau181, pTau231 and [F]MK6240 tau-PET <i>EBioMedicine</i> , <b>2022</b> , 76, 103837	8.8	1
280	Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer's disease <i>Neuropsychopharmacology</i> , <b>2022</b> ,	8.7	3
279	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility <i>Nature Reviews Neurology</i> , <b>2022</b> ,	15	4
278	Soluble amyloid-beta isoforms predict downstream Alzheimer's disease pathology <i>Cell and Bioscience</i> , <b>2021</b> , 11, 204	9.8	0
277	Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, [4], and Cognitive Impairment. <i>Neurology</i> , <b>2021</b> , 96, e975-e985	6.5	7
276	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , <b>2021</b> , 78, 1471-1483	17.2	18
275	Co-registration of Imaging Modalities (MRI, CT and PET) to Perform Frameless Stereotaxic Robotic Injections in the Common Marmoset. <i>Neuroscience</i> , <b>2021</b> , 480, 143-154	3.9	O
274	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2021</b> ,	5.9	2
273	18F-MK-6240 tau-PET in genetic frontotemporal dementia. <i>Brain</i> , <b>2021</b> ,	11.2	1
272	Amyloid-dependent and amyloid-independent effects of Tau in individuals without dementia. <i>Annals of Clinical and Translational Neurology</i> , <b>2021</b> , 8, 2083-2092	5.3	1
271	Elderly Man Repeating Questions about Upcoming Appointments <b>2021</b> , 14-17		
270	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. <i>Alzheimern</i> s <i>Research and Therapy</i> , <b>2021</b> , 13, 69	9	10
269	Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer's disease. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 251	8.6	11
268	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. <i>Brain Communications</i> , <b>2021</b> , 3, fcab073	4.5	7
267	Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer's disease. <i>Molecular Neurodegeneration</i> , <b>2021</b> , 16, 28	19	9

# (2021-2021)

266	Interactive rather than independent effect of and sex potentiates tau deposition in women. <i>Brain Communications</i> , <b>2021</b> , 3, fcab126	4.5	3
265	In vivo hippocampal cornu ammonis 1-3 glutamatergic abnormalities are associated with temporal lobe epilepsy surgery outcomes. <i>Epilepsia</i> , <b>2021</b> , 62, 1559-1568	6.4	O
264	A multicenter comparison of [F]flortaucipir, [F]RO948, and [F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2295-2305	8.8	11
263	Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis. <i>Neurology</i> , <b>2021</b> ,	6.5	23
262	Artificial intelligence for molecular neuroimaging. Annals of Translational Medicine, 2021, 9, 822	3.2	1
261	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , <b>2021</b> , 12, 3400	17.4	51
260	Association of plasma P-tau181 with memory decline in non-demented adults. <i>Brain Communications</i> , <b>2021</b> , 3, fcab136	4.5	3
259	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. <i>Biological Psychiatry</i> , <b>2021</b> , 89, 776-785	7.9	13
258	Determining Amyloid-Positivity Using F-AZD4694 PET Imaging. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 247-252	8.9	20
257	The effects of exercise on sleep quality in persons with Parkinson's disease: A systematic review with meta-analysis. <i>Sleep Medicine Reviews</i> , <b>2021</b> , 55, 101384	10.2	12
256	Machine Learning in Nuclear Medicine: Part 2-Neural Networks and Clinical Aspects. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 22-29	8.9	3
255	Diagnostic Impact of Cerebrospinal Fluid Biomarkers in Atypical Dementias in Canada. <i>Canadian Journal of Neurological Sciences</i> , <b>2021</b> , 48, 312-320	1	
254	Topographic Distribution of Amyloid-[]Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease. <i>Neurology</i> , <b>2021</b> , 96, e81-e92	6.5	10
253	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , <b>2021</b> , 26, 429-442	15.1	70
252	Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease. <i>Translational Neurodegeneration</i> , <b>2021</b> , 10, 1	10.3	5
251	Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia. <i>NeuroImage: Clinical</i> , <b>2021</b> , 29, 102552	5.3	O
250	Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease. <i>Alzheimeri</i> s and Dementia: Translational Research and Clinical Interventions, <b>2021</b> , 7, e12154	6	1
249	Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer's disease. <i>NeuroImage: Clinical</i> , <b>2021</b> , 31, 102733	5.3	7

248	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , <b>2021</b> , 141, 709-724	14.3	83
247	Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans. <i>Journal of Psychiatry and Neuroscience</i> , <b>2021</b> , 46, E1-E13	4.5	3
246	Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and cognitively unimpaired individuals. <i>Translational Neurodegeneration</i> , <b>2021</b> , 10, 11	10.3	3
245	Preclinical longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2021</b> , 271678X211035625	7.3	1
244	Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , <b>2021</b> , 27, 1592-159	<b>9</b> 30.5	44
243	FEOBV-PET to quantify cortical cholinergic denervation in AD: Relationship to basal forebrain volumetry. <i>Journal of Neuroimaging</i> , <b>2021</b> , 31, 1077-1081	2.8	O
242	Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease. <i>Alzheimern</i> and <i>Dementia</i> , <b>2021</b> ,	1.2	2
241	Molecular Imaging of the Cholinergic System in Alzheimer and Lewy Body Dementias: Expanding Views. <i>Current Neurology and Neuroscience Reports</i> , <b>2021</b> , 21, 52	6.6	2
240	Author Response: Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, [4], and Cognitive Impairment <i>Neurology</i> , <b>2021</b> , 97, 609	6.5	O
239	Preliminary Evaluations of [C]Verubulin: Implications for Microtubule Imaging With PET. <i>Frontiers in Neuroscience</i> , <b>2021</b> , 15, 725873	5.1	O
238	Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [F]-FEOBV. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 91, 162-166	3.6	3
237	Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. <i>Brain</i> , <b>2021</b> ,	11.2	6
236	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimern</i> and Dementia, <b>2021</b> , 17, 1145-1156	1.2	48
235	Neuroinflammation imposes vulnerability to tau propagation. <i>Alzheimeri</i> s and Dementia, <b>2020</b> , 16, e039	8 <u>1</u> 18	
234	Cholinergic Modulation of Binocular Vision. <i>Journal of Neuroscience</i> , <b>2020</b> , 40, 5208-5213	6.6	4
233	APOEI potentiates the relationship between amyloid-Dand tau pathologies. <i>Molecular Psychiatry</i> , <b>2020</b> ,	15.1	23
232	Topographical distribution of Alpredicts progression to dementia in Alpositive mild cognitive impairment. <i>Alzheimerns and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2020</b> , 12, e12037	5.2	4
231	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. <i>Molecular Psychiatry</i> , <b>2020</b> ,	15.1	8

# (2020-2020)

2	30	Guidelines for the content and format of PET brain data in publications and archives: A consensus paper. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2020</b> , 40, 1576-1585	7.3	26
2.	29	Intermediate flortaucipir uptake is associated with AEPET and CSF tau in asymptomatic adults. <i>Neurology</i> , <b>2020</b> , 94, e1190-e1200	6.5	18
2.	28	Morphometric network differences in ageing versus Alzheimer's disease dementia. <i>Brain</i> , <b>2020</b> , 143, 635-649	11.2	14
2.	27	Mild behavioral impairment is associated with Eamyloid but not tau or neurodegeneration in cognitively intact elderly individuals. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, 192-199	1.2	60
2.	26	Association of Vascular Risk Factors With EAmyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use. <i>JAMA Network Open</i> , <b>2020</b> , 3, e1920780	10.4	17
2.	25	CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. Alzheimers and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12098	6	0
2.	24	Frontotemporal dementia and COVID-19: Hypothesis generation and roadmap for future research. <i>Alzheimeri</i> s and Dementia: Translational Research and Clinical Interventions, <b>2020</b> , 6, e12085	6	1
2.	23	Frontal Variant of Alzheimer Disease Differentiated From Frontotemporal Dementia Using in Vivo Amyloid and Tau Imaging. <i>Cognitive and Behavioral Neurology</i> , <b>2020</b> , 33, 288-293	1.6	3
2.	22	Efficient radiosynthesis and preclinical evaluation of [F]FOMPyD as a positron emission tomography tracer candidate for TrkB/C receptor imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2020</b> , 63, 144-150	1.9	1
2.	21	Association of Apolipoprotein E & With Medial Temporal Tau Independent of Amyloid-[] <i>JAMA Neurology</i> , <b>2020</b> , 77, 470-479	17.2	71
2.	20	18F-MK-6240 PET for early and late detection of neurofibrillary tangles. <i>Brain</i> , <b>2020</b> , 143, 2818-2830	11.2	65
2	19	Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. <i>Brain</i> , <b>2020</b> , 143, 3793-3804	11.2	20
2	18	Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. <i>Alzheimerrs and Dementia</i> , <b>2020</b> , 16, 1182-1195	1.2	48
2	17	CCCDTD5: research diagnostic criteria for Alzheimer's Disease. <i>Alzheimen</i> and <i>Dementia: Translational Research and Clinical Interventions</i> , <b>2020</b> , 6, e12036	6	1
2	16	Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials. Dementia and Geriatric Cognitive Disorders, <b>2020</b> , 49, 334-348	2.6	12
2	15	Suicidal ideation is common in autosomal dominant Alzheimer's disease at-risk persons.  International Journal of Geriatric Psychiatry, 2020, 35, 60-68	3.9	1
2	14	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology, The</i> , <b>2020</b> , 19, 422-433	24.1	286
2	13	Dynamic H-MRS for detection of C-labeled glucose metabolism in the human brain at 3T. <i>Magnetic Resonance in Medicine</i> , <b>2020</b> , 84, 1140-1151	4.4	2

212	Inferior Longitudinal Fasciculus' Role in Visual Processing and Language Comprehension: A Combined MEG-DTI Study. <i>Frontiers in Neuroscience</i> , <b>2019</b> , 13, 875	5.1	14
211	Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. <i>Nature Communications</i> , <b>2019</b> , 10, 4227	17.4	77
210	Rostral-Caudal Hippocampal Functional Convergence Is Reduced Across the Alzheimer's Disease Spectrum. <i>Molecular Neurobiology</i> , <b>2019</b> , 56, 8336-8344	6.2	2
209	No apparent effect of naproxen on CSF markers of innate immune activation. <i>Annals of Clinical and Translational Neurology</i> , <b>2019</b> , 6, 1127-1133	5.3	2
208	Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation. <i>Alzheimern</i> and Dementia, <b>2019</b> , 15, 951-960	1.2	14
207	Allnduced vulnerability propagates via the brain's default mode network. <i>Nature Communications</i> , <b>2019</b> , 10, 2353	17.4	39
206	AB4 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. <i>Nature Communications</i> , <b>2019</b> , 10, 2240	17.4	20
205	First-in-Human Brain Imaging of [F]TRACK, a PET tracer for Tropomyosin Receptor Kinases. <i>ACS Chemical Neuroscience</i> , <b>2019</b> , 10, 2697-2702	5.7	9
204	PET imaging of freely moving interacting rats. <i>NeuroImage</i> , <b>2019</b> , 191, 560-567	7.9	13
203	Cholinergic Potentiation Alters Perceptual Eye Dominance Plasticity Induced by a Few Hours of Monocular Patching in Adults. <i>Frontiers in Neuroscience</i> , <b>2019</b> , 13, 22	5.1	15
202	Diagnostic Approach of Early-Onset Dementia with Negative Family History: Implications from Two Cases of Early-Onset Alzheimer's Disease with De Novo PSEN1 Mutation. <i>Journal of Alzheimerns Disease</i> , <b>2019</b> , 68, 551-558	4.3	11
201	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimerrs and Dementia</i> , <b>2019</b> , 15, 742-753	1.2	50
200	INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. <i>Neurology</i> , <b>2019</b> , 92, e2070-e2080	6.5	47
199	Machine Learning in Nuclear Medicine: Part 1-Introduction. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 451-4	1 <b>58</b> .9	22
198	PET Imaging of Perceptual Learning-Induced Changes in the Aged Rodent Cholinergic System. <i>Frontiers in Neuroscience</i> , <b>2019</b> , 13, 1438	5.1	1
197	Reliability and Validity of the Chinese Version of the Mild Behavioral Impairment Checklist for Screening for Alzheimer's Disease. <i>Journal of Alzheimeris Disease</i> , <b>2019</b> , 70, 747-756	4.3	13
196	Consequences of Metabolic Disruption in Alzheimer's Disease Pathology. <i>Neurotherapeutics</i> , <b>2019</b> , 16, 600-610	6.4	24
195	Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [F]THK5351 uptake in progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , <b>2019</b> , 24, 102091	5.3	12

#### (2018-2019)

194	Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 1398	5.6	10
193	Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images. <i>Alzheimerns and Dementia: Translational Research and Clinical Interventions</i> , <b>2019</b> , 5, 610-617	6	22
192	In vivo metabotropic glutamate receptor type 5 abnormalities localize the epileptogenic zone in mesial temporal lobe epilepsy. <i>Annals of Neurology</i> , <b>2019</b> , 85, 218-228	9.4	11
191	Astrocyte Biomarkers in Alzheimer's Disease. <i>Trends in Molecular Medicine</i> , <b>2019</b> , 25, 77-95	11.5	108
190	Regional Amyloid-Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia. <i>Molecular Neurobiology</i> , <b>2019</b> , 56, 4916-4924	6.2	14
189	A simplified radiosynthesis of [F]MK-6240 for tau PET imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2019</b> , 62, 109-114	1.9	7
188	Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging. <i>Pharmaceuticals</i> , <b>2019</b> , 12,	5.2	6
187	Constrained instruments and their application to Mendelian randomization with pleiotropy. <i>Genetic Epidemiology</i> , <b>2019</b> , 43, 373-401	2.6	11
186	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. <i>Neurobiology of Aging</i> , <b>2019</b> , 77, 169-177	5.6	24
185	Phantom bedside intruder in Parkinson's disease. <i>Neurology and Clinical Neuroscience</i> , <b>2019</b> , 7, 91-93	0.3	O
184	Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment. <i>Journal of Alzheimerrs Disease</i> , <b>2018</b> , 64, S23-S31	4.3	8
183	variant mitigates Alzheimer disease pathophysiology in vivo and postmortem. <i>Neurology: Genetics</i> , <b>2018</b> , 4, e216	3.8	5
182	Proximity to Parental Symptom Onset and Amyloid-Burden in Sporadic Alzheimer Disease. <i>JAMA Neurology</i> , <b>2018</b> , 75, 608-619	17.2	16
181	Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis. <i>Journal of Alzheimeris Disease</i> , <b>2018</b> , 63, 577-590	4.3	21
180	Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 1021-1030	8.8	20
179	Anosognosia predicts default mode network hypometabolism and clinical progression to dementia. <i>Neurology</i> , <b>2018</b> , 90, e932-e939	6.5	41
178	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , <b>2018</b> , 3, 463-472	3.4	30
177	Identification of [F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging. <i>Journal of Medicinal Chemistry</i> , <b>2018</b> , 61, 1737-1743	8.3	25

176	Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to. <i>Experimental Gerontology</i> , <b>2018</b> , 107, 169-177	4.5	22
175	Principal component of explained variance: An efficient and optimal data dimension reduction framework for association studies. <i>Statistical Methods in Medical Research</i> , <b>2018</b> , 27, 1331-1350	2.3	7
174	Characterizing biomarker features of cognitively normal individuals with ventriculomegaly. <i>Alzheimern</i> and Dementia: Diagnosis, Assessment and Disease Monitoring, <b>2018</b> , 10, 12-21	5.2	4
173	Optimal use of cholinergic drugs in Alzheimer's disease. <i>Brain</i> , <b>2018</b> , 141, e68	11.2	1
172	Reduced resting-state functional connectivity of the basolateral amygdala to the medial prefrontal cortex in preweaning rats exposed to chronic early-life stress. <i>Brain Structure and Function</i> , <b>2018</b> , 223, 3711-3729	4	28
171	In vivo quantification of neurofibrillary tangles with [F]MK-6240. <i>Alzheimerns Research and Therapy</i> , <b>2018</b> , 10, 74	9	69
170	Impact of the biological definition of Alzheimer's disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?. <i>Translational Neurodegeneration</i> , <b>2018</b> , 7, 12	10.3	14
169	Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease. <i>Alzheimerns Research and Therapy</i> , <b>2018</b> , 10, 80	9	30
168	Clinical Meaningfulness of Biomarker Endpoints in Alzheimer Disease Research. <i>Neuromethods</i> , <b>2018</b> , 235-248	0.4	
167	Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease. <i>Human Brain Mapping</i> , <b>2018</b> , 39, 971-984	5.9	24
166	The influence of language and culture on cognitive assessment tools in the diagnosis of early cognitive impairment and dementia. <i>Expert Review of Neurotherapeutics</i> , <b>2018</b> , 18, 859-869	4.3	13
165	Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease. <i>Translational Neurodegeneration</i> , <b>2018</b> , 7, 23	10.3	28
164	PET/CT of Dementia. American Journal of Roentgenology, 2018, 211, 246-259	5.4	11
163	Test-retest variability of [C]ABP688 estimates of metabotropic glutamate receptor subtype 5 availability in humans. <i>Synapse</i> , <b>2018</b> , 72, e22041	2.4	13
162	Amyloid-land hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease. <i>Molecular Psychiatry</i> , <b>2017</b> , 22, 306-311	15.1	86
161	[F]FDG PET signal is driven by astroglial glutamate transport. <i>Nature Neuroscience</i> , <b>2017</b> , 20, 393-395	25.5	144
160	Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimer's Disease. <i>IEEE Transactions on Medical Imaging</i> , <b>2017</b> , 36, 1758-1768	11.7	43
159	Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. <i>Neurology</i> , <b>2017</b> , 88, 1814-1821	6.5	49

158	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimerrs and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 8, 111-126	5.2	128
157	The prevalence and biomarkers' characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database. <i>Alzheimeri</i> s and Dementia: Translational Research and Clinical Interventions, <b>2017</b> , 3, 107-113	6	12
156	Synergistic interaction between amyloid and tau predicts the progression to dementia. <i>Alzheimerns and Dementia</i> , <b>2017</b> , 13, 644-653	1.2	57
155	Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. <i>Neurology</i> , <b>2017</b> , 89, 1931	6.5	
154	Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer's Disease. <i>Journal of Alzheimer</i> Disease, <b>2017</b> , 60, 1589-1600	4.3	28
153	Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [F]-FEOBV. <i>Molecular Psychiatry</i> , <b>2017</b> , 22, 1531-1538	15.1	62
152	Identifying incipient dementia individuals using machine learning and amyloid imaging. <i>Neurobiology of Aging</i> , <b>2017</b> , 59, 80-90	5.6	61
151	Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities. Journal of Neuroscience, <b>2017</b> , 37, 12263-12271	6.6	28
150	A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human. <i>Journal of Medicinal Chemistry</i> , <b>2017</b> , 60, 6897-691	1 <mark>6</mark> 8.3	14
149	Monoamine oxidase B inhibitor, selegiline, reduces F-THK5351 uptake in the human brain. <i>Alzheimern</i> Research and Therapy, <b>2017</b> , 9, 25	9	213
148	Odor identification as a biomarker of preclinical AD in older adults at risk. <i>Neurology</i> , <b>2017</b> , 89, 327-335	6.5	74
1 4 <del>7</del>			
147	[P4B06]: COMPARISON BETWEEN MONOAMINE OXIDASE B INHIBITION ON THE UPTAKE OF [18F]THK5351 <b>2017</b> , 13, P1533-P1534		
146			
	[18F]THK5351 <b>2017</b> , 13, P1533-P1534  [P4B66]: ASSESSING THE IMPACT OF INFLAMMATION ON LIMBIC CIRCUITRY AND ITS ROLE IN		
146	[18F]THK5351 <b>2017</b> , 13, P1533-P1534  [P4B66]: ASSESSING THE IMPACT OF INFLAMMATION ON LIMBIC CIRCUITRY AND ITS ROLE IN DEPRESSION IN OLDER ADULTS <b>2017</b> , 13, P1569  [O2B4D2]: PRECLINICAL ASSESSMENT OF KAL-ABP TARGET ENGAGEMENT AND EFFICACY USING	3.3	14
146 145	[18F]THK5351 2017, 13, P1533-P1534  [P4B66]: ASSESSING THE IMPACT OF INFLAMMATION ON LIMBIC CIRCUITRY AND ITS ROLE IN DEPRESSION IN OLDER ADULTS 2017, 13, P1569  [O2B4D2]: PRECLINICAL ASSESSMENT OF KAL-ABP TARGET ENGAGEMENT AND EFFICACY USING PET, MRI AND CSF BIOMARKERS 2017, 13, P591-P592  Cholinergic Potentiation Improves Perceptual-Cognitive Training of Healthy Young Adults in Three	3.3 o.8	14
146 145 144	[18F]THK5351 2017, 13, P1533-P1534  [P4B66]: ASSESSING THE IMPACT OF INFLAMMATION ON LIMBIC CIRCUITRY AND ITS ROLE IN DEPRESSION IN OLDER ADULTS 2017, 13, P1569  [O2d4D2]: PRECLINICAL ASSESSMENT OF KAL-ABP TARGET ENGAGEMENT AND EFFICACY USING PET, MRI AND CSF BIOMARKERS 2017, 13, P591-P592  Cholinergic Potentiation Improves Perceptual-Cognitive Training of Healthy Young Adults in Three Dimensional Multiple Object Tracking. Frontiers in Human Neuroscience, 2017, 11, 128  Wrappers Feature Selection in Alzheimer's Biomarkers Using kNN and SMOTE Oversampling. TeMa,		

P2-053: Amyloid-Induced Microglial Activity in Thalamocortical Circuits Predicts Subsequent Cognitive Decline **2016**, 12, P627-P628

139	Remodeling of Neuronal Circuits After Reach Training in Chronic Capsular Stroke.  Neurorehabilitation and Neural Repair, <b>2016</b> , 30, 941-950	4.7	9
138	In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD. <i>Brain Structure and Function</i> , <b>2016</b> , 221, 1387-402	4	26
137	Sensory-parietal cortical stimulation improves motor recovery in severe capsular infarct. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2016</b> , 36, 2211-2222	7-3	6
136	Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [(11)C]ABP688 PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 152-162	8.8	35
135	Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients. <i>CONTINUUM Lifelong Learning in Neurology</i> , <b>2016</b> , 22, 615-8	3	3
134	Combination Therapy of Anti-Tau and Anti-Amyloid Drugs for Disease Modification in Early-stage Alzheimer's Disease: Socio-economic Considerations Modeled on Treatments for Tuberculosis, HIV/AIDS and Breast Cancer. <i>journal of prevention of Alzheimerrs disease, The</i> , <b>2016</b> , 3, 164-172	3.8	10
133	Dementia and Bioethics. <i>Mental Health and Illness Worldwide</i> , <b>2016</b> , 1-13	0.1	
132	Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging. <i>Cerebral Cortex</i> , <b>2016</b> , 26, 4170-4179	5.1	15
131	Imaging Alzheimer's disease pathophysiology with PET. Dementia E Neuropsychologia, 2016, 10, 79-90	2.1	21
130	VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis. <i>Frontiers in Neuroinformatics</i> , <b>2016</b> , 10, 20	3.9	44
129	Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada. <i>Canadian Journal of Neurological Sciences</i> , <b>2016</b> , 43, 503-12	1	22
128	Is ApoE e 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease?. <i>Translational Neurodegeneration</i> , <b>2016</b> , 5, 20	10.3	14
127	A dataset of multiresolution functional brain parcellations in an elderly population with no or mild cognitive impairment. <i>Data in Brief</i> , <b>2016</b> , 9, 1122-1129	1.2	1
126	IC-P-027: Amyloid-Induced Microglial Activity in Thalamocortical Circuits Predicts Subsequent Cognitive Decline <b>2016</b> , 12, P28-P29		
125	IC-P-025: [18F]Florbetapir Roc Curve at Every Voxel Revels a Wide Range of Cortical Suvr Cut-Offs <b>2016</b> , 12, P27-P28		
124	P1-251: Synergism between Brain Amyloid Accumulation and Neuronal Injury in Cortical-Subcortical Circuits Causes Memory Declines in Animal Models <b>2016</b> , 12, P504-P505		
123	P1-282: Voxel-Wise Logistic Regression Improves Prediction Accuracy for Developing Alzheimer's Disease <b>2016</b> , 12, P527-P527		

122	IC-P-086: Amyloid-land Hyperphosphorylated TAU Synergy Drives Clinical Progression to Alzheimer Disease <b>2016</b> , 12, P66-P67		
121	IC-P-099: Synergism Between Brain Amyloid Accumulation and Neuronal Injury in Cortical-Subcortical Circuits Causes Memory Declines in Animal Models <b>2016</b> , 12, P75-P76		
120	P2-093: Polymorphism in Cytochrome P450 Gene is Associated with Alzheimer∄ Pathology <b>2016</b> , 12, P646-P646		
119	IC-P-101: Synergism Between Baseline Amyloidosis and Neuronal Injury as Determinants of Learning Deficits in AD Transgenic Rat Model <b>2016</b> , 12, P77-P77		
118	IC-P-157: Novel Toolbox for Performing Voxel-Wise Generalized Linear Regression With Mulitple Volumetric Covariates in Longitudinal Data <b>2016</b> , 12, P116-P117		
117	P3-221: Synergism Between Baseline Amyloidosis and Neuronal Injury as Determinants of Learning Deficits in Alzheimer's Disease Transgenic Rat Model <b>2016</b> , 12, P910-P910		
116	IC-P-159: Voxel-Wise Logistic Regression Improves Prediction Accuracy for Developing AD <b>2016</b> , 12, F	P117-P1	18
115	P3-251: Novel Toolbox for Performing Voxel-Wise Generalized Linear Regression with Mulitple Volumetric Covariates in Longitudinal Data <b>2016</b> , 12, P925-P926		
114	O5-02-06: The Association between white Matter Hyperintensities and Memory Impairment Depends on P-TAU Levels in a High-Risk Cohort of Aging Cognitively Normal Persons <b>2016</b> , 12, P381-I	P381	
113	P4-310: The Effect of Lumbar Puncture on the Retention of the Prevent-ad Cohort ad <b>2016</b> , 12, P115	2-P1152	
112	Deletion of the mu opioid receptor gene in mice reshapes the reward-aversion connectome.  Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11603-116	08 <sup>11.5</sup>	40
111	Le diagnostic prEoce de la maladie dAlzheimer : panacë ou catastrophe ?. Ethics, Medicine and Public Health, <b>2015</b> , 1, 151-154	0.7	1
110	Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2015</b> , 35, 1169-74	7.3	32
109	Syntheses and evaluation of carbon-11- and fluorine-18-radiolabeled pan-tropomyosin receptor kinase (Trk) inhibitors: exploration of the 4-aza-2-oxindole scaffold as Trk PET imaging agents. <i>ACS Chemical Neuroscience</i> , <b>2015</b> , 6, 260-76	5.7	19
108	Deficit in sustained attention following selective cholinergic lesion of the pedunculopontine tegmental nucleus in rat, as measured with both post-mortem immunocytochemistry and in vivo PET imaging with [I] fluoroethoxybenzovesamicol. <i>Behavioural Brain Research</i> , <b>2015</b> , 278, 107-14	3.4	24
107	P3-133: Association between apolipoprotein a-i levels and white matter hyperintensities depends on CSF tau levels in a high-risk cohort of aging cognitively normal persons: The prevent-alzheimer's disease study <b>2015</b> , 11, P674-P675		
106	P4-097: Should a global or a regional measure of amyloidosis be used in a longitudinal study? <b>2015</b> , 11, P811-P811		
105	FTS-04-03: Clinical utility of amyloid PET in the differential diagnosis of atypical dementias and its impact on caregivers <b>2015</b> , 11, P264-P264		

104	Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer's disease. <i>Scientific Data</i> , <b>2015</b> , 2, 150043	8.2	24
103	IC-P-011: Comparison of global and voxel-based diagnostic classification using [18F]florbetapir ROC estimates <b>2015</b> , 11, P18-P19		
102	IC-P-012: Should a global or a regional measure of amyloidosis be used in a longitudinal study? <b>2015</b> , 11, P19-P19		1
101	IC-P-027: Dynamics of longitudinal biomarker changes in the Mcgill-R-Thy1-APP RAT <b>2015</b> , 11, P27-P28		
100	Epistasis analysis links immune cascades and cerebral amyloidosis. <i>Journal of Neuroinflammation</i> , <b>2015</b> , 12, 227	10.1	8
99	Common Effects of Amnestic Mild Cognitive Impairment on Resting-State Connectivity Across Four Independent Studies. <i>Frontiers in Aging Neuroscience</i> , <b>2015</b> , 7, 242	5.3	18
98	IC-P-026: Amyloidosis induces reorganization of the hippocampal metabolic network <b>2015</b> , 11, P27-P27		
97	Development of subnanomolar radiofluorinated (2-pyrrolidin-1-yl)imidazo[1,2-b]pyridazine pan-Trk inhibitors as candidate PET imaging probes. <i>MedChemComm</i> , <b>2015</b> , 6, 2184-2193	5	16
96	P1-036: Dynamics of longitudinal biomarker changes in the Mcgill-R-Thy1-APP rat <b>2015</b> , 11, P350-P351		
95	P3-180: Comparison of global and voxel-based diagnostic classification using [18F]florbetapir ROC estimates <b>2015</b> , 11, P699-P699		
94	IC-P-155: Baseline CSF p-tau and fibrillary amyloid load predict mesial temporal hypometabolism in 24-months follow-up in cognitively normal subjects <b>2015</b> , 11, P104-P104		
93	P1-159: Amyloidosis induces reorganization of the hippocampal metabolic network <b>2015</b> , 11, P405-P40	6	
92	P1-177: Extensive white matter burden represents a new radiological phenotype in a distinct population of ad patients <b>2015</b> , 11, P412-P413		
91	O5-01-06: Baseline CSF p-tau and fibrillary amyloid load predict mesial temporal hypometabolism in 24 months' follow-up in cognitively normal subjects <b>2015</b> , 11, P314-P315		
90	MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research. <i>Trends in Neurosciences</i> , <b>2014</b> , 37, 629-41	13.3	32
89	Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging. <i>Journal of Neuroinflammation</i> , <b>2014</b> , 11, 120	10.1	66
88	Amyloid imaging in Alzheimer disease: a potential new era of personalized medicine?. <i>Translational Neuroscience</i> , <b>2014</b> , 5,	1.2	1
87	Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2014</b> , 21, 143-8	2.7	23

86	Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model. <i>Neurobiology of Disease</i> , <b>2014</b> , 68, 126-36	7.5	105
85	Limbic system mGluR5 availability in cocaine dependent subjects: a high-resolution PET [(11)C]ABP688 study. <i>NeuroImage</i> , <b>2014</b> , 98, 195-202	7.9	48
84	IC-P-176: EPISTASIS ANALYSES INDICATE ASSOCIATION BETWEEN CEREBRAL AMYLOID DEPOSITION AND GENES INVOLVED IN IMMUNO-RESPONSE <b>2014</b> , 10, P98-P99		
83	Resting state executive control network adaptations in amnestic mild cognitive impairment. Journal of Alzheimerns Disease, <b>2014</b> , 40, 993-1004	4.3	23
82	P1-049: EPISTASIS ANALYSES INDICATE ASSOCIATION BETWEEN CEREBRAL AMYLOID DEPOSITION AND GENES INVOLVED IN IMMUNORESPONSE <b>2014</b> , 10, P321-P321		
81	How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?. <i>Neurodegenerative Diseases</i> , <b>2014</b> , 13, 197-9	2.3	3
80	Nonamyloid PET biomarkers and Alzheimer's disease: current and future perspectives. <i>Future Neurology</i> , <b>2014</b> , 9, 597-613	1.5	2
79	Developments in Tau PET Imaging. Canadian Journal of Neurological Sciences, 2014, 41, 547-53	1	40
78	In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals. <i>Translational Neurodegeneration</i> , <b>2014</b> , 3, 6	10.3	21
77	PET imaging with [H]fluoroethoxybenzovesamicol ([H]FEOBV) following selective lesion of cholinergic pedunculopontine tegmental neurons in rat. <i>Nuclear Medicine and Biology</i> , <b>2014</b> , 41, 96-101	2.1	16
76	Impact of scale space search on age- and gender-related changes in MRI-based cortical morphometry. <i>Human Brain Mapping</i> , <b>2013</b> , 34, 2113-28	5.9	17
75	Concordance between in vivo and postmortem measurements of cholinergic denervation in rats using PET with [18F]FEOBV and choline acetyltransferase immunochemistry. <i>EJNMMI Research</i> , <b>2013</b> , 3, 70	3.6	12
74	Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. <i>Alzheimerns Research and Therapy</i> , <b>2013</b> , 5, S3	9	20
73	Role of emerging neuroimaging modalities in patients with cognitive impairment: a review from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. <i>Alzheimerns Research and Therapy</i> , <b>2013</b> , 5, S4	9	14
72	Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. <i>Alzheimerns Research and Therapy</i> , <b>2013</b> , 5, S8	9	14
71	Towards tropomyosin-related kinase B (TrkB) receptor ligands for brain imaging with PET: radiosynthesis and evaluation of 2-(4-[(18)F]fluorophenyl)-7,8-dihydroxy-4H-chromen-4-one and 2-(4-([N-methyl-(11)C]-dimethylamino)phenyl)-7,8-dihydroxy-4H-chromen-4-one. <i>Bioorganic and</i>	3.4	20
70	Diagnosis and management of Alzheimer's disease: past, present and future ethical issues. <i>Progress in Neurobiology</i> , <b>2013</b> , 110, 102-13	10.9	73
69	Cholinergic Depletion in Alzheimer's Disease Shown by [ (18) F]FEOBV Autoradiography.  International Journal of Molecular Imaging, 2013, 2013, 205045		28

68	Distinct increased metabotropic glutamate receptor type 5 (mGluR5) in temporal lobe epilepsy with and without hippocampal sclerosis. <i>Hippocampus</i> , <b>2013</b> , 23, 1212-30	3.5	37
67	Dementia: Disclosure of results to participants in dementia research. <i>Nature Reviews Neurology</i> , <b>2013</b> , 9, 608-9	15	2
66	Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-land cerebrovascular pathology. <i>PLoS ONE</i> , <b>2013</b> , 8, e686	5₹2	62
65	White matter abnormalities and structural hippocampal disconnections in amnestic mild cognitive impairment and Alzheimer's disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e74776	3.7	23
64	Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study. <i>Brain Research Bulletin</i> , <b>2012</b> , 87, 406-12	3.9	27
63	Prevention strategies for Alzheimer's disease. <i>Translational Neurodegeneration</i> , <b>2012</b> , 1, 13	10.3	17
62	Diagnosis of Alzheimer disease <b>2012</b> , 12-46		
61	PET imaging of cholinergic deficits in rats using [18F]fluoroethoxybenzovesamicol ([18F]FEOBV). <i>NeuroImage</i> , <b>2012</b> , 62, 555-61	7.9	28
60	Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. Journal of Neuroscience, <b>2012</b> , 32, 4705-15	6.6	125
59	Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). <i>Canadian Geriatrics Journal</i> , <b>2012</b> , 15, 120-6	2.8	98
58	Test-retest stability of cerebral mGluR[quantification using [IIIC]ABP688 and positron emission tomography in rats. <i>Synapse</i> , <b>2012</b> , 66, 552-60	2.4	30
57	Early-onset familial Alzheimer's disease (EOFAD). <i>Canadian Journal of Neurological Sciences</i> , <b>2012</b> , 39, 436-45	1	126
56	4e Conffence canadienne consensuelle sur le diagnostic et le traitement de la dihence. <i>Canadian Journal of Neurological Sciences</i> , <b>2012</b> , 39, S1-S8	1	
55	4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. <i>Canadian Journal of Neurological Sciences</i> , <b>2012</b> , 39, S1-8	1	19
54	Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. <i>PLoS ONE</i> , <b>2012</b> , 7, e47905	3.7	40
53	Advances in Alzheimer⊠ disease management <b>2012</b> , 2-3		
52	Age-related alterations in the modular organization of structural cortical network by using cortical thickness from MRI. <i>NeuroImage</i> , <b>2011</b> , 56, 235-45	7.9	130
51	Superficially located white matter structures commonly seen in the human and the macaque brain with diffusion tensor imaging. <i>Brain Connectivity</i> , <b>2011</b> , 1, 37-47	2.7	31

# (2008-2011)

50	Intact memory in TGF-II transgenic mice featuring chronic cerebrovascular deficit: recovery with pioglitazone. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2011</b> , 31, 200-11	7.3	33
49	Use of biomarkers in clinical trials of Alzheimer disease: from concept to application. <i>Molecular Diagnosis and Therapy</i> , <b>2011</b> , 15, 313-25	4.5	15
48	In vivo and in vitro validation of reference tissue models for the mGluR(5) ligand [(11)C]ABP688. Journal of Cerebral Blood Flow and Metabolism, <b>2010</b> , 30, 1538-49	7.3	51
47	Motion compensation for fully 4D PET reconstruction using PET superset data. <i>Physics in Medicine and Biology</i> , <b>2010</b> , 55, 4063-82	3.8	9
46	Multi-level bootstrap analysis of stable clusters in resting-state fMRI. <i>NeuroImage</i> , <b>2010</b> , 51, 1126-39	7.9	237
45	Atlas-guided tract reconstruction for automated and comprehensive examination of the white matter anatomy. <i>Neurolmage</i> , <b>2010</b> , 52, 1289-301	7.9	226
44	Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar. <i>NeuroImage</i> , <b>2010</b> , 49, 1406-15	7.9	41
43	Transgenic mice overexpressing APP and transforming growth factor-beta1 feature cognitive and vascular hallmarks of Alzheimer's disease. <i>American Journal of Pathology</i> , <b>2010</b> , 177, 3071-80	5.8	45
42	TLN-4601 peripheral benzodiazepine receptor (PBR/TSPO) binding properties do not mediate apoptosis but confer tumor-specific accumulation. <i>Biochemical Pharmacology</i> , <b>2010</b> , 80, 1572-9	6	12
41	Motion-compensated fully 4D PET reconstruction using PET data supersets 2009,		4
41	Motion-compensated fully 4D PET reconstruction using PET data supersets <b>2009</b> ,  Age- and gender-related differences in the cortical anatomical network. <i>Journal of Neuroscience</i> , <b>2009</b> , 29, 15684-93	6.6	500
	Age- and gender-related differences in the cortical anatomical network. <i>Journal of Neuroscience</i> , <b>2009</b> , 29, 15684-93  [18FlSiFA-isothiocyanate: a new highly effective radioactive labeling agent for lysine-containing	6.6	
40	Age- and gender-related differences in the cortical anatomical network. <i>Journal of Neuroscience</i> , <b>2009</b> , 29, 15684-93  [18F]SiFA-isothiocyanate: a new highly effective radioactive labeling agent for lysine-containing	2	500
40	Age- and gender-related differences in the cortical anatomical network. <i>Journal of Neuroscience</i> , <b>2009</b> , 29, 15684-93  [18F]SiFA-isothiocyanate: a new highly effective radioactive labeling agent for lysine-containing proteins. <i>ChemBioChem</i> , <b>2009</b> , 10, 1321-4  Robust S1, S2, and thalamic activations in individual subjects with vibrotactile stimulation at 1.5 and 3.0 T. <i>Human Brain Mapping</i> , <b>2009</b> , 30, 1328-37	3.8	500
4º 39 38	Age- and gender-related differences in the cortical anatomical network. <i>Journal of Neuroscience</i> , <b>2009</b> , 29, 15684-93  [18F]SiFA-isothiocyanate: a new highly effective radioactive labeling agent for lysine-containing proteins. <i>ChemBioChem</i> , <b>2009</b> , 10, 1321-4  Robust S1, S2, and thalamic activations in individual subjects with vibrotactile stimulation at 1.5 and 3.0 T. <i>Human Brain Mapping</i> , <b>2009</b> , 30, 1328-37  MicroPET imaging of 5-HT 1A receptors in rat brain: a test-retest [18F]MPPF study. <i>European</i>	3.8 5.9	500 37 12
40 39 38 37	Age- and gender-related differences in the cortical anatomical network. <i>Journal of Neuroscience</i> , <b>2009</b> , 29, 15684-93  [18F]SiFA-isothiocyanate: a new highly effective radioactive labeling agent for lysine-containing proteins. <i>ChemBioChem</i> , <b>2009</b> , 10, 1321-4  Robust S1, S2, and thalamic activations in individual subjects with vibrotactile stimulation at 1.5 and 3.0 T. <i>Human Brain Mapping</i> , <b>2009</b> , 30, 1328-37  MicroPET imaging of 5-HT 1A receptors in rat brain: a test-retest [18F]MPPF study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36, 53-62  Design, construction, and validation of an MRI-compatible vibrotactile stimulator intended for clinical use. <i>Journal of Neuroscience Methods</i> , <b>2009</b> , 184, 129-35	3.8 5.9 8.8	500 37 12
40 39 38 37 36	Age- and gender-related differences in the cortical anatomical network. <i>Journal of Neuroscience</i> , 2009, 29, 15684-93  [18F]SiFA-isothiocyanate: a new highly effective radioactive labeling agent for lysine-containing proteins. <i>ChemBioChem</i> , 2009, 10, 1321-4  Robust S1, S2, and thalamic activations in individual subjects with vibrotactile stimulation at 1.5 and 3.0 T. <i>Human Brain Mapping</i> , 2009, 30, 1328-37  MicroPET imaging of 5-HT 1A receptors in rat brain: a test-retest [18F]MPPF study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 53-62  Design, construction, and validation of an MRI-compatible vibrotactile stimulator intended for clinical use. <i>Journal of Neuroscience Methods</i> , 2009, 184, 129-35  Time-efficient and convenient synthesis of [(18)F]altanserin for human PET imaging by a new	3.8 5.9 8.8 3	500 37 12 14 21

32	Human brain white matter atlas: identification and assignment of common anatomical structures in superficial white matter. <i>NeuroImage</i> , <b>2008</b> , 43, 447-57	7.9	378
31	Accelerated microPET Transmission Imaging. IEEE Transactions on Nuclear Science, 2008, 55, 2501-2507	1.7	
30	Revealing modular architecture of human brain structural networks by using cortical thickness from MRI. <i>Cerebral Cortex</i> , <b>2008</b> , 18, 2374-81	5.1	356
29	Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. <i>Journal of Neuroscience</i> , <b>2008</b> , 28, 9287-96	6.6	227
28	Development of FMRI techniques for planning in functional neurosurgery for Parkinson disease <b>2008</b> ,		1
27	Radiosynthesis of cis-4-[124I]iodo-L-proline as a prototype probe for imaging anterograde axoplasmic transport systems using positron emission tomography (PET). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2007</b> , 50, 636-637	1.9	
26	Brain regional alpha-[11C]methyl-L-tryptophan trapping, used as an index of 5-HT synthesis, in healthy adults: absence of an age effect. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2007</b> , 34, 1254-64	8.8	15
25	Mapping the amphetamine-evoked changes in [11C]raclopride binding in living rat using small animal PET: modulation by MAO-inhibition. <i>NeuroImage</i> , <b>2007</b> , 35, 38-46	7.9	30
24	Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study. <i>NeuroImage</i> , <b>2006</b> , 30, 26-35	7.9	46
23	alpha-[11C]Methyl-L-tryptophan trapping in the orbital and ventral medial prefrontal cortex of suicide attempters. <i>European Neuropsychopharmacology</i> , <b>2006</b> , 16, 220-3	1.2	100
22	Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. <i>NeuroImage</i> , <b>2005</b> , 25, 868-76	7.9	110
21	Stability of alpha-[11C]methyl-L-tryptophan brain trapping in healthy male volunteers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2005</b> , 32, 1199-204	8.8	13
20	Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. <i>International Review of Neurobiology</i> , <b>2005</b> , 63, 1-20	4.4	45
19	MDMA-evoked changes in cerebral blood flow in living porcine brain: correlation with hyperthermia. <i>Synapse</i> , <b>2004</b> , 53, 214-21	2.4	18
18	MDMA-evoked changes in [11C]raclopride and [11C]NMSP binding in living pig brain. <i>Synapse</i> , <b>2004</b> , 53, 222-33	2.4	34
17	Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET. <i>Neurolmage</i> , <b>2004</b> , 22, 1076-1076	7.9	
16	Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET. <i>NeuroImage</i> , <b>2004</b> , 22, 1076-83	7.9	25
15	Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. <i>Archives of General Psychiatry</i> , <b>2004</b> , 61, 556-63		98

#### LIST OF PUBLICATIONS

14	Effects of acute nicotine on hemodynamics and binding of [11C]raclopride to dopamine D2,3 receptors in pig brain. <i>NeuroImage</i> , <b>2003</b> , 19, 1127-36	9	61
13	Surgical resection for intractable epilepsy in "double cortex" syndrome yields inadequate results. <i>Epilepsia</i> , <b>2001</b> , 42, 1124-9	4	50
12	Introduction to the diagnosis of dementia1-5		
11	Young man with slow cognitive decline277-281		
10	Dosimetry of PET tracers in mice using microPET scans as an input function		1
9	Mapping neurotransmitter systems to the structural and functional organization of the human neocortex		3
8	Mapping neurotransmitter systems to the structural and functional organization of the human neocortex		4
7	Subtypes of functional brain connectivity as early markers of neurodegeneration in Alzheimer disease		1
6	Open Science Datasets from PREVENT-AD, a Longitudinal Cohort of Pre-symptomatic Alzheimer Disease		5
5	Impact of long- and short-range fiber depletion on the cognitive deficits of fronto-temporal dementia		1
4	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer∄ Disease Neuroimaging Initiative		1
3	Stable brain PET metabolic networks using a multiple sampling scheme		1
2	The calcium sensor synaptotagmin-1 is critical for phasic axonal dopamine release in the striatum and mesencephalon, but is dispensable for basic motor behaviors in mice		1
1	Biomarker modeling of Alzheimer disease using PET-based Braak staging. <i>Nature Aging</i> ,		2